Drug Trial Radar · NCT07052253
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
Last checked: Nov 19, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jul 18, 2025
Primary completion
May 10, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- Collaborators
- TransThera Sciences (Nanjing), Inc.
- First posted
- Jul 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An Open-label, Multicenter, Phase II Clinical Study of AK104/AK112 in Combination with TT-00420 Tablet in Patients with Advanced Hepatocellular Carcinoma(HCC).
Conditions
- Hepatocellular Carcinoma (HCC)
Interventions
TT-00420 (tinengotinib)Drug
oral
AK104Drug
intravenous
AK112Drug
intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Union Hospital Tongji Medical College Huazhong University of Science And Technology
Wuhan, China, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.